利用计算机预测与去免疫化方法开发低免疫原性全功能凝血因子VIII
研究通过计算机预测FVIII序列中潜在免疫原性T细胞表位并进行氨基酸替换,生成含19个替换的部分去免疫化FVIII。该分子功能完全且结构相似,体外树突状细胞-T细胞实验显示健康供者T辅助细胞增殖显著低于未修饰FVIII,提示免疫原性降低。
要点
- 计算机预测结合氨基酸替换可生成部分去免疫化FVIII。
- 修饰后FVIII保留全功能且体外免疫原性显著降低。
- 该策略可能降低血友病A患者抑制物发生风险。
核心结论
- 计算机预测成功获得部分去免疫化FVIII,体外证实其功能完全且免疫原性降低。
研究设计与样本
- 研究进行计算机预测T细胞表位并替换氨基酸,评估修饰rFVIII功能与结构相似性,并用体外实验验证免疫原性。
主要发现
- 生成含19个氨基酸替换的部分去免疫化全功能FVIII分子。
- 替换降低免疫原性评分,体外树突状细胞-T细胞实验显示健康供者T辅助细胞对修饰FVIII增殖少于未修饰FVIII。
关键数值与推荐
- 原文报告高达30%的血友病A患者产生针对输注FVIII的抑制性抗体。
临床怎么用
- 该去免疫化FVIII策略可能减少血友病A患者抑制物风险,提供更安全治疗。
局限性
- 免疫原性降低仅在体外实验验证,尚未在体内或临床研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up to 30% of hemophilia A patients develop inhibitory antibodies against the infused factor VIII (FVIII). The development of a deimmunized FVIII is an unmet high medical need. Although improved recombinant FVIII (rFVIII) products evolved within the last years, the immunogenicity has not been solved. A deimmunized FVIII could reduce the probability of inhibitor development, providing safer therapy. OBJECTIVE: To develop a deimmunized FVIII molecule by modifying major histocompatibility complex (MHC) class II presentation, leading to a functional but less immunogenic molecule. METHODS: We performed (1) in silico prediction of potentially immunogenic T cell epitopes and their modification by amino acid substitutions in the FVIII sequence, (2) evaluation of functional and structural similarity of the modified rFVIII to unmodified FVIII and registered products, and (3) confirmation of the reduced immunogenicity by in vitro testing. RESULTS: A partially deimmunized fully functional FVIII molecule incorporating 19 amino acid substitutions was generated. The substitutions led to a reduction of the immunogenicity score, indicating a reduced immunogenicity based on in silico calculations. This was confirmed in an in vitro dendritic cell (DC)--T cell assay. Using this assay, cells from healthy donors proved the significantly reduced immunogenicity of the modified FVIII variant by revealing less proliferation of T helper cells to this variant than to the unmodified FVIII. CONCLUSION: In silico predictions resulted in a partially deimmunized FVIII. This FVIII is fully functional and was demonstrated to be less immunogenic in in vitro testing. This approach may result in a reduction of the inhibitor risk for patients with hemophilia A.
引用
- Winterling K, Martin WD, De Groot AS, et al. Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach. J Thromb Haemost. 2021. PMID: 34060724. doi:10.1111/jth.15413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。